Get the Stockscreener App
178.71
0.04%
0.07
Iqvia Holdings Inc stock is traded at $178.71, with a volume of 1.08M.
It is up +0.04% in the last 24 hours and up +3.58% over the past month.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
See More
Previous Close:
$178.64
Open:
$182.43
24h Volume:
1.08M
Relative Volume:
0.51
Market Cap:
$29.83B
Revenue:
$16.30B
Net Income/Loss:
$1.36B
P/E Ratio:
22.74
EPS:
7.8573
Net Cash Flow:
$2.05B
1W Performance:
+13.27%
1M Performance:
+3.58%
6M Performance:
-15.09%
1Y Performance:
+16.58%
1-Day Range:
$175.28
$182.62
1-Week Range:
$156.62
$182.70
52-Week Range:
$134.65
$247.04
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
178.71 | 29.83B | 16.30B | 1.36B | 2.05B | 7.8573 |
TMO
Thermo Fisher Scientific Inc
|
465.00 | 172.80B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
171.16 | 121.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.11 | 44.18B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
355.13 | 34.86B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.62 | 32.67B | 7.07B | 1.29B | 993.00M | 4.5355 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Mar-06-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
Why IQVIA Holdings (IQV) Is Up 12.8% After Q1 Beat and Bigger Buyback Plan – And What's Next - simplywall.st
IQVIA Holdings stock (US46266C1053): Data?driven healthcare analytics in focus for US investors - AD HOC NEWS
IQVIA board authorizes additional $2B in share repurchases - MSN
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MSN
IQVIA Expands Share Repurchase Authorization by $2 Billion - The Globe and Mail
Here's why you should retain IQV stock in your portfolio now - MSN
BMO Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $210 - Moomoo
IQVIA Holdings Inc. (NYSE:IQV) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
IQVIA Holdings | 8-K: Current report - Moomoo
Earnings Update: IQVIA Holdings Inc. (NYSE:IQV) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
IQVIA Increases Share Repurchase Authorization by $2 Billion, Bringing Total to $3.2 Billion 1 - Minichart
Artificial Intelligence in Epidemiology Market Is Going - openPR.com
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization - The National Law Review
IQVIA Board Approves $2B Increase to Share Repurchase Authorization, $3.2B Remaining - TradingView
IQVIA board authorizes additional $2 billion stock buyback By Investing.com - Investing.com Australia
IQVIA (NYSE: IQV) boosts buyback plan, $3.2B now authorized - Stock Titan
8 Stocks Yet to Join the Rally With Upside Potential of Up to 85% - Investing.com
IQVIA Holdings (IQV) Q1 earnings and revenues beat estimates - MSN
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Contineum Therapeutics, Inc. Class A (CTNM) and Exelixis (EXEL) - The Globe and Mail
Barclays Sticks to Their Buy Rating for IQVIA Holdings (IQV) - The Globe and Mail
IQVIA Holdings (IQV) Earnings Growth And 8.3% Margin Keep Backlog Narrative In Question - Sahm
IQVIA CFO to Speak at Bank of America Health Care Conference 2026 - BioSpace
IQVIA Holdings Hits Day High with 9.62% Surge in Stock Price - Markets Mojo
Citigroup Maintains IQVIA Holdings (IQV) Neutral Recommendation - MSN
IQVIA Holdings | 8-K: IQVIA Reports First-Quarter 2026 Results - Moomoo
IQVIA Holdings Inc. announces an Increase in Equity Buyback. - marketscreener.com
IQVIA's Growth Setup Looks Positive After Q1 Beat, RBC Says - Moomoo
BMO Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $210 - Moomoo
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN) and IQVIA Holdings (IQV) - The Globe and Mail
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $210 to $240 - Moomoo
Here's What Key Metrics Tell Us About IQVIA (IQV) Q1 Earnings - Yahoo Finance
IQVIA Holdings Inc. (NYSE:IQV) Q1 2026 Earnings Call Transcript - Insider Monkey
IQVIA Q1 2026 earnings preview - MSN
IQVIA shares drop as book-to-bill ratio misses expectations - Investing.com
TD Cowen Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $213 - Moomoo
Research Alert: CFRA Maintains Buy Rating On Shares Of Iqvia - Moomoo
IQVIA Holdings Inc. Q1 2026 Financial Results: Earnings, Balance Sheet, and SEC Filing Highlights - Minichart
IQVIA Q1 2026 slides: revenue climbs 8.4%, guidance raised By Investing.com - Investing.com South Africa
IQVIA jumps 9.6% as Q1 results top expectations and full-year EPS outlook rises - Quiver Quantitative
William Blair Maintains IQVIA Holdings(IQV.US) With Buy Rating - Moomoo
IQVIA HOLDINGS INC. 1Q 2026: Revenue $4.15B, EPS $1.61— 10-Q Summary - TradingView
IQVIA Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
IQVIA (NYSE: IQV) grows Q1 2026 revenue to $4.15B and boosts EPS - Stock Titan
IQVIA signals raised 2026 adjusted EPS outlook to $12.65-$12.95 while reaffirming $17.150B-$17.350B revenue - MSN
IQVIA Holdings Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:IQV) 2026-05-05 - Seeking Alpha
IQVIA Holdings Inc Stock (IQV) Closed Up by 9.60% on May 5: Key Drivers Unveiled - TradingKey
IQVIA Holdings (IQV) Q1 2026 Earnings Call Transcript - Fortune
Trending Industry Today: IQVIA Holdings Leads Gains In CRO Stocks - Moomoo
IQV Q1 Earnings Beat on Commercial Solutions Strength - TradingView
IQVIA Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
IQVIA Q1 2026 slides: revenue climbs 8.4%, guidance raised - Investing.com
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.64%
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):